MedTrace Logo

Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer

NCT07731607 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-07-28

No results posted yet for this study

Summary

To investigate the efficacy and safety of immune checkpoint inhibitors as a non-surgical (surgery-avoiding) treatment in patients with stage I-II MSI-H/dMMR endometrial cancer.

Conditions

  • MMRd Endometrial Cancer of Stage I~II

Interventions

DRUG

Sintilimab monotherapy

Sintilimab monotherapy 200mg，Q3W

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    collaborator INDUSTRY

  • Wang Jianliu

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-20
Primary Completion
2030-07-20
Completion
2030-07-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07731607 on ClinicalTrials.gov